RU2010138638A - Новые применения 4-фенилбутирата натрия (4фб) и его фармацевтически приемлемых солей - Google Patents

Новые применения 4-фенилбутирата натрия (4фб) и его фармацевтически приемлемых солей Download PDF

Info

Publication number
RU2010138638A
RU2010138638A RU2010138638/15A RU2010138638A RU2010138638A RU 2010138638 A RU2010138638 A RU 2010138638A RU 2010138638/15 A RU2010138638/15 A RU 2010138638/15A RU 2010138638 A RU2010138638 A RU 2010138638A RU 2010138638 A RU2010138638 A RU 2010138638A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
agent
combination
brain
disease
Prior art date
Application number
RU2010138638/15A
Other languages
English (en)
Russian (ru)
Inventor
Диана-Сара ФРЕЧИЛЛА-МАНСО (ES)
Диана-Сара ФРЕЧИЛЛА-МАНСО
Ана-Мария ГАРСИЯ-ОСТА (ES)
Ана-Мария ГАРСИЯ-ОСТА
Луис-Альберто ПЕРЕС-МЕДИАВИЛЬЯ (ES)
Луис-Альберто ПЕРЕС-МЕДИАВИЛЬЯ
Ана-Лоурдес РИКОБАРАСА-АБАРКЕРО (ES)
Ана-Лоурдес РИКОБАРАСА-АБАРКЕРО
Original Assignee
Пройекто Де Биомедисина Сима, С.Л. (Es)
Пройекто Де Биомедисина Сима, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пройекто Де Биомедисина Сима, С.Л. (Es), Пройекто Де Биомедисина Сима, С.Л. filed Critical Пройекто Де Биомедисина Сима, С.Л. (Es)
Publication of RU2010138638A publication Critical patent/RU2010138638A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2010138638/15A 2008-03-13 2009-03-06 Новые применения 4-фенилбутирата натрия (4фб) и его фармацевтически приемлемых солей RU2010138638A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200800736 2008-03-13
ES200800736A ES2332687B1 (es) 2008-03-13 2008-03-13 Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.

Publications (1)

Publication Number Publication Date
RU2010138638A true RU2010138638A (ru) 2012-04-20

Family

ID=40691368

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010138638/15A RU2010138638A (ru) 2008-03-13 2009-03-06 Новые применения 4-фенилбутирата натрия (4фб) и его фармацевтически приемлемых солей

Country Status (11)

Country Link
US (1) US20110027251A1 (enExample)
EP (1) EP2272515A1 (enExample)
JP (1) JP2011518119A (enExample)
CN (1) CN102036665A (enExample)
AU (1) AU2009224613A1 (enExample)
BR (1) BRPI0909745A2 (enExample)
CA (1) CA2718463A1 (enExample)
ES (1) ES2332687B1 (enExample)
MX (1) MX2010009933A (enExample)
RU (1) RU2010138638A (enExample)
WO (1) WO2009112609A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080827A1 (es) * 2010-04-06 2012-05-09 Bayer Cropscience Ag Utilizacion del acido 4- fenil- butirico y/o de sus sales para el aumento de la tolerancia al estres en plantas
CN101973868B (zh) * 2010-11-12 2012-08-15 北京恒瑞康达医药科技发展有限公司 苯丁酸钠ⅰ型结晶及其制备方法
EP2599479A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-phenylbutyric acid for the treatment of alzheimer's disease
WO2013149091A1 (en) 2012-03-29 2013-10-03 The Regents Of The University Of Colorado, A Body Corporate Composition and method for treating neurodegenerative disease
CN102757334B (zh) * 2012-07-30 2014-05-28 北京恒瑞康达医药科技发展有限公司 苯丁酸钠ⅱ型晶体及其制备方法
US9872865B2 (en) * 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
EP3019865A4 (en) * 2013-07-12 2017-04-05 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
US11224668B2 (en) * 2016-02-29 2022-01-18 Neurovation Labs, Inc. Compositions and methods to detect GluA1 in brain and to identify the presence of GluA1-mediated PTSD
IL296490B1 (en) 2016-03-15 2025-09-01 Acer Therapeutics Inc Tasty compositions containing sodium phenylbutyrate and their uses
JP6962572B2 (ja) * 2016-03-18 2021-11-05 学校法人同志社 ２，４−ジアミノフェノール誘導体、及び、タウ及び／又はアミロイドβの凝集阻害剤
JP2019214546A (ja) * 2018-06-11 2019-12-19 学校法人福岡大学 終末糖化産物生成抑制剤及び医薬組成物
JP2020083827A (ja) * 2018-11-27 2020-06-04 国立研究開発法人農業・食品産業技術総合研究機構 ケミカルシャペロンまたは神経細胞死の抑制剤
WO2020139874A1 (en) * 2018-12-27 2020-07-02 Virginia Polytechnic Institute And State University Chemically programmed neutrophils and uses thereof
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US20240108593A1 (en) * 2020-12-07 2024-04-04 University Of Miami Method of treating polyamine imbalance-related disorders
JP2024543053A (ja) * 2021-11-08 2024-11-19 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 神経変性疾患の治療のための胆汁酸及びフェニルブチレート化合物の組合せ
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
CN116099003A (zh) * 2022-11-28 2023-05-12 核工业总医院 内质网应激抑制剂在放射性认知功能障碍药物中的应用
WO2024165757A1 (en) 2023-02-10 2024-08-15 Ludwig-Maximilians-Universität München Oral phenylbutyrate for treatment of human 4-repeat tauopathies
CN117338763A (zh) * 2023-11-01 2024-01-05 重庆医科大学 丁酸钠在制备治疗帕金森病的药物中的应用及其治疗新靶标

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
DE69706566T2 (de) * 1996-08-13 2002-07-11 P.N. Gerolymatos S.A., Kruoneri Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US6664297B1 (en) * 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
WO2002090534A1 (en) * 2001-05-02 2002-11-14 The Regents Of The University Of California Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate

Also Published As

Publication number Publication date
JP2011518119A (ja) 2011-06-23
US20110027251A1 (en) 2011-02-03
CN102036665A (zh) 2011-04-27
WO2009112609A1 (es) 2009-09-17
CA2718463A1 (en) 2009-09-17
ES2332687A1 (es) 2010-02-10
BRPI0909745A2 (pt) 2019-09-24
MX2010009933A (es) 2010-12-06
ES2332687B1 (es) 2011-01-10
EP2272515A1 (en) 2011-01-12
AU2009224613A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
RU2010138638A (ru) Новые применения 4-фенилбутирата натрия (4фб) и его фармацевтически приемлемых солей
JP2011518119A5 (enExample)
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
EA200801492A1 (ru) Фармацевтическое применение замещенных амидов
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
BRPI0607017B8 (pt) composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
WO2007112000A3 (en) Treatment of pain
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
EA201300314A1 (ru) Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство
WO2006078424A3 (en) Polyherbal compositions and methods for treating viral infections
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
BR0014895A (pt) Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais
BRPI0409151A (pt) uso de derivados de 10-hidróxi-10,11-diidrocarbamazepina para o tratamento de transtornos afetivos
DK1656131T3 (da) Anvendelse af betain til behandling claudicatio intermittens
ATE481094T1 (de) Behandlung von diabetischer nephropathie
BR0105787A (pt) Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico
EA202000347A1 (ru) ПРОТИВО-SARS-CoV-2 ВИРУСНОЕ СРЕДСТВО АНТИПРОВИР
RU2006101150A (ru) Композиции нестероидных противовоспалительных средств для лечения патологического ангиогенеза глаз
EA200601666A1 (ru) Комбинированная фармацевтическая композиция для ингибирования ухудшения когнитивных функций
EA200400394A1 (ru) Фармацевтическая композиция для лечения диабетической невропатии

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130517